Chorea, particularly Sydenham's chorea, remains an important public health problem in many parts of the world. Chorea is among the most challenging neurologic disorders to treat. There is still no consensus regarding appropriate treatment other than penicillin prophylaxis for SC. A decision to treat chorea should be based upon patient disability and an awareness of the risk-benefit and side effect profiles of the various treatment options. Studies to date are limited and comprise primarily case reports and retrospective reviews. The limited data, however, support pharmacologic therapy as the logical first step, with anticonvulsants such as valproic acid or carbamazepine as the initial drugs of choice in most circumstances. Polytherapy may be necessary, and rational drug combinations would include a dopamine receptor blocker (higher risk of tardive dyskinesia) or a GABAmimetic drug such as clonazepam. Immunomodulatory and surgical therapies remain investigational. Additional large, randomized, controlled studies are needed to further explore therapy for chorea.
|Original language||English (US)|
|Title of host publication||Treatment of Pediatric Neurologic Disorders|
|Number of pages||6|
|ISBN (Print)||0824726936, 9780824726935|
|State||Published - Jan 1 2005|
ASJC Scopus subject areas